SCHEMBL14747229

SCHEMBL14747229

Cc1cc(O)ccc1C(=O)Cc1ccc(O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.69
SHBG P04278 1/20 0.69
ESR2 Q92731 1/20 0.69
LMNA P02545 4/20 0.57
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
MAPT P10636 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
HTT P42858 1/20 0.57
GAA P10253 1/20 0.57
ALOX12 P18054 1/20 0.57
ALDH1A1 P00352 3/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
HPGD P15428 2/20 0.56
CYP3A4 P08684 1/20 0.56
ATM Q13315 1/20 0.56
ALOX5 P09917 1/20 0.49
CA2 P00918 2/20 0.47
CAMK2A Q9UQM7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11517499 0.90 LMNA (0.60) ESR1SHBGESR2LMNANPC1
SCHEMBL312243 0.81 ESR1 (1.00) ESR1SHBGESR2LMNANPC1
SCHEMBL30503014 0.81 ESR1 (1.00) ESR1SHBGESR2LMNANPC1
SCHEMBL8663113 0.81 NPC1 (0.51) ESR1SHBGESR2LMNANPC1
SCHEMBL7253586 0.79 HSP90AB1 (0.69) ESR1SHBGESR2LMNAHTT
SCHEMBL27735150 0.79 HSP90AB1 (0.53) ESR1SHBGESR2LMNANPC1
SCHEMBL3820741 0.79 ESR1 (0.81) ESR1SHBGESR2LMNANPC1
SCHEMBL13640734 0.79 ESR1 (0.75) ESR1SHBGESR2LMNANPC1
SCHEMBL38652384 0.79 ESR1 (0.81) ESR1SHBGESR2LMNANPC1
SCHEMBL22887515 0.79 MRGPRX4 (0.50) ESR1SHBGESR2LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389548-B2 Administering an estrogen receptor for treatment of osteoporosis, breast cancer, hypercholesteremia, hyperlipidemia or artheriosclerosis by administering estrogen modulators ENDORECHERCHE, INC. (CA) 2013-03-05 US disclosed
US-8389548-B2 Administering an estrogen receptor for treatment of osteoporosis, breast cancer, hypercholesteremia, hyperlipidemia or artheriosclerosis by administering estrogen modulators ENDORECHERCHE, INC. (CA) 2013-03-05 US disclosed